Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Solithromycin versus moxifloxacin for adult community-acquired bacterial pneumonia
2012-003971-20Phase 3Completed
- Sponsor
- Cempra
- Start
- Feb 2013
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Covalent Small Molecules → Small Molecules, Nucleic Acid-Directed Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in community acquired pneumonia (CAP) comparing Oral solithromycin with Oral moxifloxacin (2 arms). Primary endpoints: Early clinical response rate in ITT population and Early clinical response definition. Started Feb 2013; status: completed.
02
Drugs
solithromycinmoxifloxacin
03
Conditions
community acquired pneumonia (CAP)
Beyond the preview
Go deeper on 2012-003971-20.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2012-003971-20.